The Prevalence of Transmitted Resistance to First-Generation Non-Nucleoside Reverse Transcriptase Inhibitors and Its Potential Economic Impact in HIV-Infected Patients

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Snedecor, Sonya J ^a   Khachatryan, Alexandra ^a   Nedrow, Katherine ^b   Chambers, Richard ^b   Li, Congyu ^a   Haider, Seema ^b   Stephens, Jennifer ^a  

^a PHARMERIT INTERNATIONAL   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; EUROPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NONHUMAN; PREVALENCE; SYSTEMATIC REVIEW; UNITED STATES; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; COST OF ILLNESS; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84882802110     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072784     Document Type: Article

References (67)

1. IAS (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308: 387-402. doi:10.1001/jama.2012.7961. PubMed: 22820792.
2. EACS (2012) European AIDS Clinical Society (EACS) guidelines. Available: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.1-English-Nov2012.pdf. Accessed 11 December 2012.
3. DHHS (2011) uidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
4. Corbau R, Mori J, Phillips C, Fishburn L, Martin A, et al. (2010) Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 54: 4451-4463. doi:10.1128/AAC.01455-09. PubMed: 20660667.
5. Ghosn J, Chaix ML, Delaugerre C, (2009) HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Res 11: 165-173. PubMed: 19654858.
6. Holodniy M, Charlebois ED, Bangsberg DR, Zolopa AR, Schulte M, et al. (2004) Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study. Int J STD AIDS 15: 543-551. doi:10.1258/0956462041558212. PubMed: 15307966.
7. Kagan R, Winters M, Merigan T, Heseltine P, (2004) HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res Hum Retrovir 20: 1-9. doi:10.1089/088922204322749440. PubMed: 15000693.
8. Rahim S, Fredrick LM, da Silva BA, Bernstein B, King MS, (2009) Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials 10: 94-103. doi:10.1310/hct1002-94. PubMed: 19487179.
9. Frentz D, Boucher CA, van de Vijver DA, (2012) Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Res 14: 17-27. PubMed: 22297501.
10. Shet A, Markowitz M, (2006) Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches. Curr Opin Investig Drugs 7: 709-720. PubMed: 16955682.
11. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, et al. (2010) Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLOS ONE 5: e15510. doi:10.1371/journal.pone.0015510. PubMed: 21170322.
12. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298-303. doi:10.1093/nar/gkg100. PubMed: 12520007.
13. Shafer RW, (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194 Suppl 1: S51-S58 doi:10.1086/505356. PubMed: 16921473.
14. Jain V, Pilcher CD, Deeks SG, Liegler T, (2009) Increasing Prevalence of NNRTI-Associated Drug Resistance Mutations in Patients with Acute/Early HIV in San Francisco. Conference on Retrovirueses and Opportunistic Infections Poster # 673.
15. Kim D, Ziebell R, Saduvala N, Kline R, Banez Ocfemia C, et al. (2013) Trend in Transmitted HIV-1 ARV Drug Resistance-associated Mutations: 10 HIV Surveillance Areas, US, 2007-2010. 20th Conference on Retrovir and Opportunistic Infections paper #149.
16. Brumme CJ, (2012) Trends in HIV-1 resistance prevalence at the community level following the expansion of access to antiretroviral treatment in British Columbia, Canada. International Workshop HIV Hepat Virus Drugs Resist Curative Strategies Abstract 141.
17. Brenner B, Charest H, Roger M, Oliveira M, (2012) Spread of Sub-epidemics Resistant to Non-nucleoside Analogues Among Treatment-Naïve MSM: Montreal. Conference on Retrovirueses and Opportunistic Infections Abstract 731.
18. Yang W, (2012) 15-Year Prevalence Data of Transmitted Drug Resistance Shows a Positive Association with Mean Population Viral Load of Treatment-failing Patients from the Previous Year. Conference on Retroviruses and Opportunistic Infections Abstract 735.
19. de Mendoza C, Rodriguez C, Colomina J, Tuset C, Garcia F, et al. (2005) Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 41: 1350-1354. doi:10.1086/496982. PubMed: 16206115.
20. Yerly S, Junier T, Gayet-Ageron A, Amari EB, von W, et al V,. (2009) The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 23: 1415-1423. doi:10.1097/QAD.0b013e32832d40ad. PubMed: 19487906.
21. Youmans E, Tripathi A, Albrecht H, Gibson JJ, Duffus WA, (2011) Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. South Med J 104: 95-101. doi:10.1097/SMJ.0b013e3181fcd75b. PubMed: 21206421.
22. Oette M, Reuter S, Kaiser R, Lengauer T, Fatkenheuer G, et al. (2012) Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA Study 2001-2009 Intervirology 55: 154-159.
23. Balduin M, Oette M, Däumer MP, Hoffmann D, Pfister HJ, et al. (2009) Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure. J Clin Virol 45: 34-38. doi:10.1016/j.jcv.2009.03.002. PubMed: 19375978.
24. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, et al. (2007) Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS 21: 825-834. doi:10.1097/QAD.0b013e32805e8764. PubMed: 17415037.
25. Richman D, Bozzette S, Morton S, (2001) The prevalence of antiretroviral drug resistance in the US. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL: Abstract LB. p. pp. 17.
26. Booth CL, Geretti AM, (2007) Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056. doi:10.1093/jac/dkm082. PubMed: 17449483.
27. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, et al. (2009) Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 23: 717-724. PubMed: 19279445.
28. Yang Q, (2011) The prevalence and determinants of transmitted drug resistance among newly diagnosed HIV cases in Canada. Can J Infect Dis Med Microbiol 22: 86B.
29. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, et al. (2009) Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200: 1503-1508. doi:10.1086/644505. PubMed: 19835478.
30. Joly V, Descamps D, Peytavin G, Touati F, Mentre F, et al. (2004) Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother 48: 172-175. doi:10.1128/AAC.48.1.172-175.2004. PubMed: 14693536.
31. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, et al. (2008) Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 82: 5510-5518. doi:10.1128/JVI.02579-07. PubMed: 18353964.
32. Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di PM, et al. (2009) Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antivir Ther 14: 359-369. PubMed: 19474470.
33. Dunn DT, Coughlin K, Cane PA, (2011) Genotypic resistance testing in routine clinical care. Curr Opin HIV Aids 6: 251-257. doi:10.1097/COH.0b013e32834732e8. PubMed: 21646877.
34. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, et al. (2010) Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLOS ONE 5: e10952. doi:10.1371/journal.pone.0010952. PubMed: 20532178.
35. Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, et al. (2009) Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLOS ONE 4: e6079. doi:10.1371/journal.pone.0006079. PubMed: 19562031.
36. Vandenhende MA, (2010) Prevalence of drug-resistant HIV-1 variants in first line antiretroviral therapy failure: comparison between population and ultra deep-sequencing ANRS CO3 Aquitaine cohort. 2000-2008. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Dubrovnik, Croatia: A127.
37. Metzner KJ, Rauch P, Walter H, Boesecke C, Zöllner B, et al. (2005) Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 19: 1819-1825. doi:10.1097/01.aids.0000189878.97480.ed. PubMed: 16227789.
38. Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, et al. (2010) Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis 201: 672-680. PubMed: 20102272.
39. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305: 1327-1335. doi:10.1001/jama.2011.375. PubMed: 21467286.
40. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, et al. (2012) Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 26: 185-192. doi:10.1097/QAD.0b013e32834e9d7d. PubMed: 22179227.
41. Boltz VF, Zheng Y, Lockman S, Hong F, Halvas EK, et al. (2011) Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 108: 9202-9207. doi:10.1073/pnas.1105688108. PubMed: 21576473.
42. Rowley CF, Boutwell CL, Lee EJ, MacLeod IJ, Ribaudo HJ, et al. (2010) Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retrovir 26: 293-300. doi:10.1089/aid.2009.0082. PubMed: 20334564.
43. Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, et al. (2009) Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 48: 462-472. doi:10.1086/596486. PubMed: 19133804.
44. Wagner T, (2009) Resistance mutations detected by oligonucleotide ligation assay of HIV-1 DNA at time of initiation of nevirapine containing antiretroviral therapy are associated with virologic failure. International Workshop HIV Hepat Virus Drugs Resist Curative Strategies A46.
45. Papathanosopoulos MA, (2012) Antiretroviral drug-resistant minority variants are significantly associate with first-line failure in antiretroviral drug-naïve patients. International Workshop HIV Hepat Virus Drugs Resist Curative Strategies A33.
46. Hernandez-Novoa B, (2009) Mutant HIV minority variants detected by ultradeep sequencing do not condition virological failure in patients starting ARV therapy including low genetic barrier drugs. IAS WEPEB208.
47. Metzner KJ, (2011) The significance of pre-existing minority Y181C mutations on virological failure of NNRTI-based first-line antiretroviral therapy. International Workshop HIV Hepat Virus Drugs Resist Curative Strategies A107.
48. Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, et al. (2011) Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLOS ONE 6: e28952. doi:10.1371/journal.pone.0028952. PubMed: 22194957.
49. Karmon S, (2012) Acquisition of transmitted HIV-1 drug resistance mutations as minority variants in a New York City cohort. Aids TUPE 258.
50. Messiaen P, Verhofstede C, Vandenbroucke I, Dinakis S, Van Eygen V, et al. (2012) Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology 426: 7-11. doi:10.1016/j.virol.2012.01.002. PubMed: 22305619.
51. Van Eygen V, (2012) Deep sequencing analysis of baseline samples from patients treated with rilpivirine in the Phase III studies ECHO and THRIVE shows no association between the presenece of minority resistance-associated variants and virological failure. International Workshop HIV Hepat Virus Drugs Resist Curative Strategies A35.
52. Craig C, (2011). Minor Species Resist Present Screen Does Not Affect Outcomes Week 48in lersivirine (UK-453,061) phase IIb study A5271015 in treatment-naive patients. IAS MOPE161.
53. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, et al. (2006) The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 44: 990-997. doi:10.1097/01.mlr.0000228021.89490.2a. PubMed: 17063130.
54. Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, et al. (2012) Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS 26: 45-56. doi:10.1097/QAD.0b013e32834dce6e. PubMed: 22008655.
55. Krentz HB, Gill MJ, (2012) The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat: pp. 2012: 757135.
56. Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, et al. (2002) Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 162: 2478-2486. doi:10.1001/archinte.162.21.2478. PubMed: 12437408.
57. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, et al. (2006) Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 42: 1003-1010. doi:10.1086/500453. PubMed: 16511767.
58. Gebo KA, Fleishman JA, Conviser R, Hellinger J, Hellinger FJ, et al. (2010) Contemporary costs of HIV healthcare in the HAART era. AIDS 24: 2705-2715. doi:10.1097/QAD.0b013e32833f3c14. PubMed: 20859193.
59. Hellinger FJ, Encinosa WE, (2010) The cost and incidence of prescribing errors among privately insured HIV patients. Pharmacoeconomics 28: 23-34. doi:10.2165/11313810-000000000-00000. PubMed: 20014874.
60. Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, et al. (2011) The cost of HIV disease in Northern Italy: the payer's perspective. J Acquir Immune Defic Syndr 57: 211-217. doi:10.1097/QAI.0b013e31821fdee2. PubMed: 21546850.
61. Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, et al. (2012) Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNA K3A Study. Eur J Health Econ.
62. Beck EJ, Mandalia S, Sangha R, Sharott P, Youle M, et al. (2011) The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. PLOS ONE 6: e27830. doi:10.1371/journal.pone.0027830. PubMed: 22194795.
63. Martin S, (2007) ncremental medical costs associated with increased changes in HAART regimens in a US patient sample. 4th. IAS Conference on HIV Pathogenesis, Treatment and Prevention.
64. Meenan RT, (2010) Incidence-based Costs of Multiple HAART Switches Among HIVinfected Patients in an HMO. Clin Med Res 8: 52. doi:10.3121/cmr.8.1.52-a.
65. Stansell J, (2000) Incremental Costs of HIV Suppression in HIV Therapeutic Failure. 17th Conference on Retroviruses and Opportunistic Infections.
66. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD, (2010) Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 44: 157-165. doi:10.1345/aph.1M359. PubMed: 19996323.
67. Ceccherini-Silberstein F, Cento V, Calvez V, Perno CF, (2010) The use of human immunodeficiency virus resistance tests in clinical practice. Clin Microbiol Infect 16: 1511-1517. doi:10.1111/j.1469-0691.2010.03353.x. PubMed: 20731678.